Back to search

The University of Edinburgh

Modulation of neuropeptide growth factor signalling by anti-cancer substance-P analogues

Abstract

dc:description.abstract

Widespread metastases are characteristic of the most aggressive form of lung cancer, small cell lung cancer (SCLC). Although initially sensitive to treatment by radio- and chemotherapy, SCLC develops chemoresistance so the 2-year survival rate remains less than 5%. The aberrant proliferation of SCLC is sustained by multiple autocrine and paracrine growth loops involving calcium mobilising neuropeptides such as vasopressin (AVP) and gastrin releasing peptide (GRP). The expression of these neuropeptides and their receptors are a hallmark of the disease and present an important target for therapeutic intervention. Analogues of substance-P, including [D-ArgI,D-Phe5,D-Trp7-9,Leu11]-substance-P (SP-D) and [Arg6,D-Trp7-9,NmePhe8]-substance-P (6-11) (SP-G), are novel anti-cancer agents which inhibit the growth of SCLC cells. Investigations into the mechanism of action of substance- P analogues on bombesin receptors revealed that in addition to blocking bombesin-induced mitogenesis and signal transduction they also have agonist activity. This unique pharmacological activity of 'biased agonism' may be centred to the growth inhibitory effects of these agents.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2006

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Tufail-Hanif, Uzma

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1842/30862

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Tufail-Hanif, Uzma. Modulation of neuropeptide growth factor signalling by anti-cancer substance-P analogues. The University of Edinburgh, 2006. http://hdl.handle.net/1842/30862